Keytruda sales show how Merck can compete in China

Despite local competition from cheaper PD-1 inhibitors, Keytruda continues to drive Merck's growth in China and its revenue globally.

The immuno-oncology drug brought in $2.6 billion in global sales for the quarter, up 63% from 2Q18 at constant exchange rates and ahead of consensus estimates

Read the full 440 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE